Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 94 P27 | DOI: 10.1530/endoabs.94.P27

SFEBES2023 Poster Presentations Adrenal and Cardiovascular (78 abstracts)

Evaluation of the hounsfield unit approach for streamlining investigations for adrenal incidentalomas

Trevor Tam 1 , Louis Saada 2 , Neetha Joseph 2 , Allison Chipchase 2 , Khin Swe Myint 1,2 & Rupa Ahluwalia 2


1University of East Anglia, Norwich, United Kingdom. 2Norfolk and Norwich University Hospital, Norwich, United Kingdom


Background: Adrenal incidentalomas (AIs) detected on pre surgical scans often present a logistical challenge due to the pressing need for preoperative exclusion of a phaeochromocytoma. Our local guideline recommends endocrinology referral for all AIs for further investigations, including pre clinic 24-hr urine metadrenalines. This approach can be time-consuming, particularly for patients awaiting unrelated surgery.

Methods: Our review included all AIs identified within our centre over a 2-year period (from 1/1/2021 to 31/12/2022). All AIs underwent unselected screening for phaeochromocytoma, including urine metadrenaline (MN) & normetadrenaline (NMN) analysis, followed by measurements of plasma MN and NMN concentrations in those with raised 24-hr urine MN/NMN concentrations.

Results: Initial analysis revealed 13 patients with elevated 24-hr urine NMN or MN levels, with 5 patients confirming elevated levels on 2 separate occasions. Subsequently only 2/13 (15.4%) patients had confirmed raised plasma normetadrenaline and/or metadrenaline concentrations, suggesting possibility of a phaeochromocytoma. On retrospective review, both these patients also had an AI with raised HU (>10 HU; recommended diagnostic threshold for pheochromocytoma screening for AIs).

Patient numberGenderAge (yr)24-hr urine NMN (F ≤ 3.0 µmol/24hr; M ≤3.8 µmol/24hr)24-hr MN (F ≤1.8 µmol/24hr; M ≤2.2 µmol/24hr)Plasma NMN (<1180 pmol/l)Plasma MN (<510 pmol/l)HU
1F665.10.512019940
2M726.96.7139279722.3

Conclusion: Our ongoing review aims to validate the guidance that early adoption of the HU approach as an initial screening tool for adrenal incidentalomas is cost-effective and clinically safe. However, practical application of this approach requires a standardised multidisciplinary assessment for all AIs including careful evaluation of all imaging, prior to undertaking endocrinology assessment, to optimise resource utilisation in clinical practice.

Volume 94

Society for Endocrinology BES 2023

Glasgow, UK
13 Nov 2023 - 15 Nov 2023

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.